Listeria-based vaccines for cancer treatment

Current Opinion in Molecular Therapeutics

Volumn 7, Issue 5, 2005, Pages 454-460

  Paterson, Yvonne ^a   Maciag, Paulo Cesar ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antigen carrier; Cancer vaccine; Cell mediated immunity; Listeria monocytogenes; Listeriosis; Tumor associated antigen

Indexed keywords

ACTIN POLYMERASE A; BETA GALACTOSIDASE; CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLYCOPROTEIN GP 70; LISTERIOLYSIN; OVALBUMIN; TUMOR ANTIGEN; TYROSINASE RELATED PROTEIN 2; UNCLASSIFIED DRUG; VIRULENCE FACTOR; VIRUS ANTIGEN; VIRUS NUCLEOPROTEIN;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; BACTERIAL COLONIZATION; CANCER IMMUNIZATION; CELL MATURATION; CYTOSOL; DRUG DELIVERY SYSTEM; DRUG POTENCY; GLIOMA; HOST CELL; IMMUNE RESPONSE; IMMUNOGENICITY; INNATE IMMUNITY; LISTERIA MONOCYTOGENES; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MURINE LEUKEMIA VIRUS; NONHUMAN; ONCOVIRINAE; PAPILLOMA; PAPILLOMA VIRUS; PHAGOCYTOSIS; PHAGOLYSOSOME; REVIEW; SAFETY; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; GENETIC VECTORS; HUMANS; LISTERIA MONOCYTOGENES; MICE; NEOPLASMS; PLASMIDS;

BACTERIA (MICROORGANISMS); LISTERIA; LISTERIA MONOCYTOGENES;

EID: 27144519154     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Dussurget O, Pizarro-Cerda J, Cossart P: Molecular determinants of Listeria monocytogenes virulence. Annu Rev Microbiol (2004) 58:587-610.
2. Pamer EG: Immune responses to Listeria monocytogenes. Nat Rev Immunol (2004) 4(10):812-823.
3. Paterson Y, Johnson RS: Progress towards the use of Listeria monocytogenes as a live bacterial vaccine vector for the delivery of HIV antigens. Expert Rev Vaccines (2004) 3(4 Suppl):S119-S134.
4. Ikonomidis G, Paterson Y, Kos FJ, Portnoy DA: Delivery of a viral antigen to the class I processing and presentation pathway by L. monocytogenes. J Exp Med (1994) 180(6):2209-2218.
5. Gunn GR, Zubair A, Paterson Y: Harnessing bacteria for cancer immunotherapy. In: Vaccines: Delivery Systems. Goebel W, Dietrich G (Eds), Horizon Scientific Press, Norwich, UK (2002):315-348.
6. Gunn GR, Zubair A, Peters CH, Pan ZK, Wu TC, Paterson Y: Two L. monocytogenes vaccine vectors that express different molecular forms of HPV-16 E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol (2001) 167(11):6471-6479.
7. Singh R, Dominiecki ME, Jaffee EM, Paterson Y: Fusion to listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals sub-dominant epitopes in the FVB/N mouse. J Immunol (2005) 175(6):3663-3673.
8. Sewell DA, Douven D, Pan ZK, Rodriguez A, Paterson Y: Regression of HPV-positive tumors treated with a new Listeria monocytogenes vaccine. Arch Otolaryngol Head Neck Surg (2004) 130(1):92-97.
9. Shen H, Slifka MK, Matloubian M, Jensen ER, Ahmed R, Miller JF: Recombinant Listeria monocytogenes as a live vaccine vehicle for the induction of protective anti-viral cell-mediated immunity. Proc Natl Acad Sci USA (1995) 92(9):3987-3991.
10. Paglia P, Arioli I, Frahm N, Chakraborty T, Colombo MP, Guzman CA: The defined attenuated Listeria monocytogenes 8 mp12 mutant is an effective oral vaccine carrier to trigger a long-lasting immune response against a mouse fibrosarcoma. Eur J Immunol (1997) 27(6):1570-1575.
11. Pope C, Kim SK, Marzo A, Masopust D, Williams K, Jiang J, Shen H, Lefrancois L: Organ-specific regulation of the CD8 T cell response to Listeria monocytogenes infection. J Immunol (2001) 166(5):3402-3409.
12. Liau LM, Jensen ER, Kremen TJ, Odesa SK, Sykes SN, Soung MC, Miller JF, Bronstein JM: Tumor immunity within the central nervous system stimulated by recombinant Listeria monocytogenes vaccination. Cancer Res (2002) 62(8):2287-2293.
13. Starks H, Bruhn KW, Shen H, Barry RA, Dubensky TW, Brockstedt D, Hinrichs DJ, Higgins DE, Miller JF, Giedlin M, Bouwer HG: Listeria monocytogenes as a vaccine vector: Virulence attenuation or existing antivector immunity does not diminish therapeutic efficacy. J Immunol (2004) 173(1):420-427.
14. Brockstedt DG, Giedlin MA, Leong ML, Bahjat KS, Gao Y, Luckett W, Liu W, Cook DN, Portnoy DA, Dubensky TW Jr. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci USA (2004) 101(38):13832-13837.
15. Lin CW, Lee JY, Tsao YP, Shen CP, Lai HC, Chen SL: Oral vaccination with recombinant Listeria monocytogenes expressing human papillomavirus type 16 E7 can cause tumor growth in mice to regress. Int J Cancer(2002) 102(6):629-637.
16. Verch T, Pan ZK, Paterson Y: Listeria monocytogenes-based antibiotic resistance gene-free antigen delivery system applicable to other bacterial vectors and DNA vaccines. Infect Immun (2004) 72(11):6418-6425.
17. Pan ZK, Ikonomidis G, Lazenby A, Pardoll D, Paterson Y: A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours. Nat Med (1995) 1(5):471-477.
18. Pan ZK, Ikonomidis G, Pardoll D, Paterson Y: Regression of established tumors in mice mediated by the oral administration of a recombinant Listeria monocytogenes vaccine. Cancer Res (1995) 55(21):4776-4779.
19. Pan ZK, Weiskirch LM, Paterson Y: Regression of established B16F10 melanoma with a recombinant Listeria monocytogenes vaccine. Cancer Res (1999) 59(20):5264-5269.
20. Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer (2001) 94(2):153-156.
21. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, Wu TC: Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res (1996) 56(1):21-26.
22. Hussain SF, Paterson Y: What is needed for effective antitumor immunotherapy? Lessons learned using Listeria monocytogenes as a live vector for HPV-associated tumors. Cancer Immunol Immunother (2005) 54(6):577-586.
23. Jensen ER, Selvakumar R, Shen H, Ahmed R, Wettstein FO, Miller JF: Recombinant Listeria monocytogenes vaccination eliminates papillomavirus-induced tumors and prevents papilloma formation from viral DNA. J Virol (1997) 71(11):8467-8474.
24. Disis ML, Cheever MA. HER-2/neu protein: A target for antigen-specific immunotherapy of human cancer. Adv Cancer Res (1997) 71:343-371.
25. Reilly RT, Gottlieb MB, Ercolini AM, Machiels JP, Kane CE, Okoye FI, Muller WJ, Dixon KH, Jaffee EM. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res (2000) 60(13):3569-3576.
26. Dominiecki ME, Beatty GL, Pan ZK, Neeson P, Paterson Y: Tumor sensitivity to IFN-γ is required for successful antigen-specific immunotherapy of a transplantable mouse tumor model for HPV-transformed tumors. Cancer Immunol Immunother (2005) 54(5):477-488.
27. Naldini A, Carraro F: Role of inflammatory mediators in angiogenesis. Curr Drug Targets Inflamm Allergy (2005) 4(1):3-8.
28. Harada N, Shimada M, Okano S, Suehiro T, Soejima Y, Tomita Y, Maehara Y: IL-12 gene therapy is an effective therapeutic strategy for hepatocellular carcinoma in immunosuppressed mice. J Immunol (2004) 173(11):6635-6644.
29. Hussain SF, Paterson Y: CD4+CD25+ regulatory T cells that secrete TGF-β and IL-10 are preferentially induced by a vaccine vector. J Immunother (2004) 27(5):339-346.
30. Sharpe AH, Freeman GJ: The B7-CD28 superfamily. Nat Rev Immunol (2002) 2(2):116-126.
31. Peng X, Hussain SF, Paterson Y: The ability of two Listeria monocytogenes vaccines targeting human papillomavirus-16 E7 to induce an antitumor response correlates with myeloid dendritic cell function. J Immunol (2004) 172(10):6030-6038.
32. Lorber B: Listeriosis. Clin Infect Dis (1997) 24(1):1-11.
33. Peters C, Domann E, Darbouche A, Chakraborty T, Mielke ME: Tailoring host immune responses to Listeria by manipulation of virulence genes - the interface between innate and acquired immunity. FEMS Immunol Med Microbiol (2003) 35(3):243-253.
34. Angelakopoulos H, Loock K, Sisul DM, Jensen ER, Miller JF, Hohmann EL: Safety and shedding of an attenuated strain of Listeria monocytogenes with a deletion of actA/plcB in adult volunteers: A dose escalation study of oral inoculation. Infect Immun (2002) 70(7):3592-3601.
35. Goossens PL, Milon G, Cossart P, Saron MF: Attenuated Listeria monocytogenes as a live vector for induction of CD8+ T cells in vivo: A study with the nucleoprotein of the lymphocytic choriomeningitis virus. Int Immunol (1995) 7(5):797-805.
36. Guzman CA, Saverino D, Medina E, Fenoglio D, Gerstel B, Merlo A, Li Pira G, Buffa F, Chakraborty T, Manca F: Attenuated Listeria monocytogenes carrier strains can deliver an HIV-1 gp120 T helper epitope to MHC class II-restricted human CD4+ T cells. Eur J Immunol (1998) 28(6):1807-1814.
37. Saklani-Jusforgues H, Fontan E, Soussi N, Milon G, Goossens PL: Enteral immunization with attenuated recombinant Listeria monocytogenes as a live vaccine vector: Organ-dependent dynamics of CD4 T lymphocytes reactive to a Leishmania major tracer epitope. Infect Immun (2003) 71(3):1083-1090.
38. Boyer JD, Robinson TM, Maciag PC, Peng X, Johnson RS, Pavlakis G, Lewis MG, Shen A, Siliciano R, Brown CR, Weiner DB et al: DNA prime Listeria boost induces a cellular immune response to SIV antigens in the rhesus macaque model that is capable of limited suppression of SIV239 viral replication. Virology (2005) 333(1):88-101.
39. Rayevskaya MV, Frankel FR: Systemic immunity and mucosal immunity are induced against human immunodeficiency virus Gag protein in mice by a new hyperattenuated strain of Listeria monocytogenes. J Virol (2001) 75(6):2786-2791.
40. Rayevskaya M, Kushnir N, Frankel FR: Safety and immunogenicity in neonatal mice of a hyperattenuated Listeria vaccine directed against human immunodeficiency virus. J Virol (2002) 76(2):918-922.
41. Cabanes D, Dehoux P, Dussurget O, Frangeul L, Cossart P: Surface proteins and the pathogenic potential of Listeria monocytogenes. Trends Microbiol (2002) 10(5):238-245.
42. Autret N, Dubail I, Trieu-Cuot P, Berche P, Charbit A: Identification of new genes involved in the virulence of Listeria monocytogenes by signature-tagged transposon mutagenesis. Infect Immun (2001) 69(4):2054-2065.
43. Kochi SK, Killeen KP, Ryan US: Advances in the development of bacterial vector technology. Expert Rev Vaccines (2003) 2(1):31-43.